These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
Filed by the Registrant
þ
|
|
|
|
Filed by a Party other than the Registrant
o
|
|
Check the appropriate box:
|
|
|
|
|
|
|
|
|
|
o
|
Preliminary Proxy Statement
|
o
|
Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
þ
|
Definitive Proxy Statement
|
|
|
|
o
|
Definitive Additional Materials
|
|
|
|
o
|
Soliciting Material Pursuant to Section 240.14a-12
|
|
|
|
þ
|
No fee required.
|
|
|
o
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
|
|
1)
|
Title of each class of securities to which transaction applies:
|
|
|
2)
|
Aggregate number of securities to which transaction applies:
|
|
|
3)
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
|
4)
|
Proposed maximum aggregate value of transaction:
|
|
|
5)
|
Total fee paid:
|
|
|
|
|
|
o
|
Fee paid previously with preliminary materials:
|
|
|
o
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
|
|
|
|
1)
|
Amount previously paid:
|
|
|
2)
|
Form, Schedule or Registration Statement No.:
|
|
|
3)
|
Filing Party:
|
|
|
4)
|
Date Filed:
|
|
|
Team Member Participation Rate
|
||
|
3YMA CAGR
(Post Dilution)
|
100%
|
50%
|
Minimum
Thresholds
|
|
20% or above
|
37%
|
18%
|
13%
|
|
11%
|
18%
|
9%
|
6%
|
|
7%
|
11%
|
5%
|
4%
|
|
Below 7%
|
0.0%
|
0.0%
|
0.0%
|
|
|
Team Member Participation Rate
|
||
|
3YMA CAGR
(Post Dilution)
|
100%
|
50%
|
Minimum
Thresholds
|
|
20% or above
|
5.2%
|
2.6%
|
1.8%
|
|
11%
|
2.6%
|
1.4%
|
0.9%
|
|
7%
|
1.5%
|
0.8%
|
0.6%
|
|
Below 7%
|
0.0%
|
0.0%
|
0.0%
|
|
PS:
|
We attempted to identify the main questions shareholders would have and have answered them in the following pages (please be sure to read the detailed program design in proposal 1 of the proxy statement). Should you have additional questions please submit them to Meredith Burns in Investor Relations at mburns@cimpress.com by Monday, April 25, 2016 and we will provide written answers on our investor relations website on or before the date we mail our definitive proxy statement. We look forward to your questions.
|
|
1)
|
Why should shareholders approve an additional 37% of Cimpress’ current shares outstanding to be authorized for issuance for this proposed compensation plan?
|
|
a.
|
In order for such dilution to ever take place, Cimpress’ long-term shareholder returns would be similar to those of the top-performing companies on Nasdaq.
|
|
b.
|
Given that shares will only be issued if the target is hit, the dilution is self-regulating in that the share dilution from the PSUs should be reflected in the future share price used to calculate the 3YMA CAGR.
|
|
c.
|
No ordinary shares actually issue until performance targets are met. For PSUs granted in the 7
th
year of the anticipated 7 years of grants funded by the authorization, this would be at least another 6 years later (i.e. 13 years from now, unless there is a change in control in the interim).
Please refer to Proposal 1 for more information.
|
|
d.
|
The 11.5 million shares is the maximum number of shares that we believe could ultimately be issued over a 13-year period assuming a 20% 3YMA CAGR post dilution. The actual number of shares we expect to be issued will be a factor of our 3YMA performance and the LTI amount team members elect to receive in PSUs. Zero shares will be issued if the 3YMA CAGR over 10 years in not at least 7%.
|
|
e.
|
The high upside opportunity of this compensation plan will reinforce an “ownership” mentality and culture in which Cimpress team members act as long-term owners, with material financial incentives which align directly with those of third-party long-term owners (like you).
|
|
2)
|
In light of this new program and your stated uppermost financial objective of maximizing IVPS, how will the company think about dilution, i.e. the “per share” component of that metric?
|
|
a.
|
The impact of dilution is important to us. One of the things we like about the equity part of this new incentive plan is that dilution only occurs if the 3YMA share price increases meaningfully, after dilution from PSUs. This is because the dilution from PSUs (which increases the denominator of the per-share metric) increases the growth of the aggregate equity value (i.e. the numerator) that is required in order for the PSUs to be settled in dilutive shares.
|
|
3)
|
Cimpress has been opportunistic about share repurchases in the past, which has kept overall dilution from share-based compensation to shareholders low/non-existent. Will that continue?
|
|
a.
|
We view share repurchases as a capital allocation choice, not a mechanism to offset dilution from equity awards. We compare repurchases to organic investments, M&A, and debt repayment and try to fund the combination of investments that we believe will help us best maximize IVPS, considering constraints like our debt covenants and management bandwidth. Because the share price fluctuates, the return profile of share repurchases also fluctuates. At times, we see share repurchases as one of the best uses of capital relative to other investments, and at other times, we may issue shares if we believe that doing so will allow us to invest greater amounts of capital at anticipated returns that comfortably exceed the cost of dilution and the cost of the new equity.
|
|
4)
|
Why is the performance metric the 3YMA share price?
|
|
a.
|
We believe the 3YMA CAGR over a 6-10 year period provides the least-flawed proxy for the change in our IVPS over the same time frame.
|
|
b.
|
We recognize this metric is not perfect (we believe a perfect metric does not exist), but we believe it is the best relative to the alternatives for the following reasons:
|
|
i.
|
Eliminates most of the volatility that otherwise often causes a substantial mismatch between our daily share price and the more enduring changes to intrinsic value.
|
|
ii.
|
Is a simple measure that both our shareholders and team members can track over time.
|
|
iii.
|
Encourages behavior and alignment among our team members that will help to maximize value over a relatively long time horizon.
|
|
5)
|
Right now, the 3YMA is significantly lower than your current stock price. You’ve also made share repurchases at roughly the same amount as your current 3YMA (and you’ve said that you hope to repurchase shares at levels that are lower than your IVPS). Doesn’t the 3YMA methodology result in too low of a valuation on which to base LTI?
|
|
a.
|
The value on which we will measure performance after 6 to 10 years is also a 3YMA CAGR. The payout relates to a percentage change between two numbers, both of which are trailing thus both of which are subject to any potential downward bias.
|
|
b.
|
Whether comparing 3YMA to IVPS, daily share price, or other metrics, we believe that there will almost always be a difference between the 3YMA and the alternative metric being compared such that sometimes the 3YMA will be above, sometimes below. We plan to make annual grants of PSUs to our team members. Given it takes a minimum of 6 years prior to any Performance Dependent Issuance, over time our executives will have five annual grants that remain subject to future performance targets. When viewed as a portfolio of grant values, we believe the differences will balance out extremes in many, if not most, cases.
|
|
6)
|
With the performance metric being tied to the share price, how can long-term shareholders feel comfortable that team members will be solely focused on making investments that return above the company’s cost of capital and that management and the supervisory board will intelligently direct the significant capital at its disposal?
|
|
a.
|
We clearly understand that share price, even over the long term and even after being reduced for volatility via the 3YMA, is not the same thing as IVPS.
|
|
b.
|
The 6-10 year time horizon is designed to help ensure decisions are made to enhance the long-term per share value of the company, rather than the short-term share price.
|
|
c.
|
We’ve established an IVPS committee consisting of our CEO, CFO, Chief Strategy Officer and members of the supervisory board. The committee’s mandate is to ensure that the company:
|
|
i.
|
Develops a culture in which team members throughout the organization understand and embrace a focus on returns-on-capital as the primary financial lens through which we should evaluate potential decisions, and understand the paramount role of capital allocation and returns as the primary driver of IVPS.
|
|
ii.
|
Develops systems to measure and track investments, to ensure accountability and to learn and improve based on both mistakes and successes in pursuit of highly effective capital allocation.
|
|
7)
|
Why is the long-term performance period longer than a more typical period of 3 or 4 years? I’m concerned that Cimpress may not show progress or drive shareholder returns in an intermediate period.
|
|
a.
|
While we believe daily share price volatility will persist as we pursue our long-term strategy, if we are not showing growth in the 3YMA CAGR in an intermediate period such as 3-4 years post grant it would make achieving a payout much harder over the 6-10 year period.
|
|
b.
|
Additionally, we plan to continue describing to shareholders on an annual basis the large investments we are making along with an assessment of whether past or current investment returns are on track versus our hurdle rates. We believe the combination of this annual visibility of in-flight projects along with an LTI plan that drives an ownership mentality among our team members should give long-term shareholders a good toolkit for holding management accountable on smart capital allocation.
|
|
c.
|
We believe a 6-10 year period is critical to reinforce a cultural message that clearly says: “We are resolutely focused on long-term value creation.”
|
|
8)
|
The proxy statement states that if a team member leaves Cimpress between a PSU vesting date but before the performance measurement date, he or she retains the vested PSUs just like a team member that is still employed by Cimpress. Why is this?
|
|
a.
|
Like our current LTI program, the new Equity Plan requires service-based vesting that may occur no faster than 25% per year for employees, and the team member has no rights to potential shares prior to such vesting. Recurring annual grants will mean that at any point in time our team members will have tranches of unvested shares that extend four years into the future. As such, we believe that this vesting
|
|
b.
|
In the new Equity Plan we compensate relative to the 3YMA share price over a minimum of six years. We think this length of time is appropriate for the purposes of calculating long-term value creation. However we do not believe it should be co-mingled or coterminous with the concept of vesting which, per the previous paragraph, we have established in function of competitiveness in compensation and retention incentives.
|
|
9)
|
What is the approximate value of this program if you look at the accounting cost that will be expensed over the life of the program (cash and shares)?
|
|
a.
|
The U.S. GAAP accounting expense reflected in our income statement will depend upon multiple factors, including how much LTI will be granted in cash retention grants versus PSUs and the difference between the 3YMA and actual share price on the date of grant. We cannot estimate this number for FY2017 today, but we should be able to comment on it at the beginning of FY 2017 after team members have made their elections.
|
|
b.
|
That being said, we believe that the annual accounting expense will be higher than our past programs. This is partly because we plan to grant PSUs deeper into the organization where we would have granted only cash LTI in the past and for this component there should be an offset in cash compensation. Additionally, based on the Monte Carlo valuation methodology that we expect to employ, there are performance scenarios in which the value of the grant is $0, there are also scenarios in which the value is significantly higher. All possible scenarios are used to determine the accounting value of the grant, and that value will be expensed through our income statement over four years (the service-based vesting period) regardless of the value that is actually delivered in year 6, 7, 8, 9 or 10.
|
|
c.
|
The impact to future cash flow will also be a function of the percentage of LTI grants that are cash-based versus PSUs. We expect to report this aggregate percentage each year. This LTI program will be replacing our prior cash LTI, restricted share units and premium-priced share option program.
|
|
10)
|
Why eliminate the annual bonus and add it, at 100% of prior target, to a team member’s base salary?
|
|
a.
|
Winning in our market requires us to be nimble and entrepreneurial. We have increasingly recognized that narrowly defined bonus metrics (such as revenue or NOPAT) established more than a year before actual decision points can inhibit crucial mid-year course corrections.
|
|
b.
|
Even worse, the impact on bonus can encourage team members to delay or forego decisions that enhance intrinsic value. For instance, improving quality and service levels may lower near-term profits (and thus bonus) but could enhance long-term intrinsic value.
|
|
c.
|
Our business is increasingly large and complex, operating across over 20 countries and many currencies, with M&A and other events that are difficult if not impossible to predict with precision. This complexity makes it both costly and inaccurate to set precise annual profit or revenue targets.
|
|
d.
|
Our team members, especially our most senior executives, will retain very large amounts of their total compensation as performance-based with greater alignment toward our uppermost financial objective of IVPS.
|
|
e.
|
Although a short-term performance metric is being eliminated, the long-term PSUs are less likely to pay out if important shorter-term milestones are not achieved along the way.
|
|
f.
|
Incentives for near-term execution performance will remain. For instance, the individual performance of team members will directly influence their personal salary levels, advancement opportunities and amount of annual LTI grants.
|
|
11)
|
How would the value created be divided between shareholders and Cimpress team members?
|
|
a.
|
We expect the vast majority of value that is created by the company to remain in the hands of long-term shareholders, as we believe is appropriate given that it is their capital that enables the company to exist.
|
|
b.
|
In percentage terms the team member portion is small relative to shareholders but, in monetary value terms, it is potentially very significant to each of them as individuals. Sharing the upside returns with the team members to such a degree is important in order to attract and retain the best talent.
|
|
•
|
signing another proxy card with a later date and delivering the new proxy card to our Chief Legal Officer at the offices of our subsidiary Cimpress USA Incorporated, 275 Wyman Street, Waltham, MA 02451 USA no later than 4:00 p.m. Eastern Standard Time on the last business day before the meeting;
|
|
•
|
delivering to our Chief Legal Officer written notice no later than 4:00 p.m. Eastern Standard Time on the last business day before the meeting that you want to revoke your proxy; or
|
|
•
|
voting in person at the meeting.
|
|
•
|
We must receive your proposal at our registered offices in Venlo, the Netherlands as set forth below no later than 60 days before the
2016
annual general meeting, and
|
|
•
|
The number of ordinary shares you hold must equal at least 3% of our issued share capital.
|
|
•
|
each shareholder we know to own beneficially more than 5% of our outstanding ordinary shares;
|
|
•
|
each member of our Supervisory Board;
|
|
•
|
our named executive officers who are listed in the Summary Compensation Table in this proxy statement; and
|
|
•
|
all of our Supervisory Board members and executive officers as a group.
|
|
Name and Address of Beneficial Owner(1)
|
|
Number of Ordinary Shares Beneficially Owned(2)
|
|
Percent of Ordinary Shares Beneficially Owned(3)
|
|
|
Arlington Value Capital, LLC(4)
|
|
2,364,205
|
|
|
7.5%
|
|
222 South Main Street, Suite 1750
|
|
|
|
|
|
|
Salt Lake City, UT 84101 USA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brave Warrior Advisors, LLC(5)
|
|
3,907,843
|
|
|
12.4
|
|
12 East 49th Street, 14th Floor
|
|
|
|
|
|
|
New York, NY 10017 USA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FMR LLC
(6)
|
|
2,755,650
|
|
|
8.8
|
|
245 Summer Street
|
|
|
|
|
|
|
Boston, MA 02210 USA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Janus Capital Management LLC(7)
|
|
1,733,643
|
|
|
5.5
|
|
151 Detroit Street
|
|
|
|
|
|
|
Denver, CO 80206 USA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Prescott General Partners LLC(8)
|
|
4,656,492
|
|
|
14.8
|
|
2200 Butts Road, Suite 320
|
|
|
|
|
|
|
Boca Raton, FL 33431 USA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Spruce House Investment Management LLC(9)
|
|
2,200,000
|
|
|
7.0
|
|
435 Hudson Street, 8th Floor
|
|
|
|
|
|
|
New York, NY 10014 USA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Executive Officers, Supervisory Board members, and Nominees for Supervisory Board
|
|
|
|
|
|
|
Robert S. Keane(10)(11)
|
|
3,452,595
|
|
|
10.4
|
|
|
|
|
|
|
|
|
Katryn S. Blake(11)
|
|
89,490
|
|
|
*
|
|
|
|
|
|
|
|
|
Paolo De Cesare(11)
|
|
17,313
|
|
|
*
|
|
|
|
|
|
|
|
|
John J. Gavin, Jr.(11)(12)
|
|
67,757
|
|
|
*
|
|
|
|
|
|
|
|
|
Donald R. Nelson(11)
|
|
142,285
|
|
|
*
|
|
|
|
|
|
|
|
|
Eric C. Olsen(11)
|
|
19,813
|
|
|
*
|
|
|
|
|
|
|
|
|
Sean E. Quinn(11)
|
|
409
|
|
|
*
|
|
|
|
|
|
|
|
|
Richard T. Riley(11)
|
|
69,921
|
|
|
*
|
|
|
|
|
|
|
|
|
Nadia Shouraboura(11)
|
|
2,218
|
|
|
*
|
|
|
|
|
|
|
|
|
Mark T. Thomas(11)(13)
|
|
34,630
|
|
|
*
|
|
|
|
|
|
|
|
|
Scott Vassalluzzo(11)(14)
|
|
142,958
|
|
|
*
|
|
|
|
|
|
|
|
|
Ernst J. Teunissen(15)
|
|
22,780
|
|
|
*
|
|
|
|
|
|
|
|
|
All current executive officers and Supervisory Board members as a group (11 persons) (11)
|
|
4,039,389
|
|
|
12.1%
|
|
*
|
Less than 1%
|
|
|
|
|
(1)
|
Unless otherwise indicated, the address of each executive officer and Supervisory Board member is c/o Cimpress N.V., Hudsonweg 8, 5928 LW Venlo, the Netherlands.
|
|
|
|
|
(2)
|
For each person or entity in the table above, the “Number of Shares Beneficially Owned” column may include ordinary shares attributable to the person or entity because of that holder’s voting or investment power or other relationship, as determined under SEC rules. Under these rules, a person or entity is deemed to have “beneficial ownership” of any shares over which that person or entity has or shares voting or investment power, plus any shares that the person or entity may acquire within 60 days of April 6, 2016 (i.e., June 5, 2016), including through the exercise of share options or the vesting of restricted share units. Unless otherwise indicated, each person or entity referenced in the table has sole voting and investment power over the shares listed or shares such power with his or her spouse. The inclusion in the table of any shares, however, does not constitute an admission of beneficial ownership of those shares by the named shareholder.
|
|
|
|
|
(3)
|
The percentage ownership for each shareholder on April 6, 2016 is calculated by dividing (1) the total number of shares beneficially owned by the shareholder by (2) 31,465,174, the number of ordinary shares outstanding on April 6, 2016, plus any shares issuable to the shareholder within 60 days after April 6, 2016 (i.e., June 5, 2016), including restricted share units that vest and share options that are exercisable on or before June 5, 2016.
|
|
|
|
|
(4)
|
This information is based solely upon a Schedule 13G that the shareholder filed with the SEC on February 16, 2016.
|
|
|
|
|
(5)
|
This information is based solely upon a Schedule 13G/A that the shareholder filed with the SEC on February 16, 2016.
|
|
|
|
|
(6)
|
This information is based solely upon a Schedule 13G/A that the shareholder filed with the SEC on February 12, 2016.
|
|
|
|
|
(7)
|
This information is based solely upon a Schedule 13G/A that the shareholder filed with the SEC on February 16, 2016.
|
|
|
|
|
(8)
|
This information is based solely upon a Schedule 13D/A that the shareholder filed with the SEC on February 17, 2016.
|
|
|
|
|
(9)
|
This information is based solely upon a Schedule 13G/A that the shareholder filed with the SEC on February 16, 2016.
|
|
|
|
|
(10)
|
Includes an aggregate of (i) 1,648,072 shares held by irrevocable discretionary trusts and other entities established for the benefit of Mr. Keane or members of his immediate family, or the Trusts, and (ii) 84,181 shares held by a charitable entity established by Mr. Keane and his spouse. Trustees who are independent of Mr. Keane or his spouse hold exclusive voting and investment power with respect to the ordinary shares owned by the Trusts and the ordinary shares issuable pursuant to share options and restricted share units held by the Trusts; Mr. Keane and his spouse do not hold such power with respect to the Trusts. Mr. Keane and his spouse share voting and investment power with respect to the shares held by the charitable entity. Mr. Keane and his spouse disclaim beneficial ownership of the shares, share options and restricted share units held by the Trusts and the charitable entity except to the extent of their pecuniary interest therein.
|
|
|
|
|
(11)
|
Includes the number of shares listed below that each executive officer and supervisory director has the right to acquire under share options and restricted share units that vest on or before June 5, 2016:
• Mr. Keane: 1,720,342 shares, held by the Trusts • Ms. Blake: 74,485 shares • Mr. De Cesare: 10,053 shares • Mr. Gavin: 39,780 shares • Mr. Nelson: 132,992 shares • Mr. Olsen: 10,053 shares • Mr. Quinn: 409 shares • Mr. Riley: 24,837 shares • Dr. Shouraboura: 2,049 shares • Mr. Thomas: 10,994 shares • Mr. Vassalluzzo: 2,049 shares • All current executive officers and supervisory directors in the aggregate: 2,028,043 shares |
|
|
|
|
(12)
|
Includes 27,977 shares owned by a trust that Mr. Gavin and his wife own.
|
|
|
|
|
(13)
|
Includes 1,800 shares owned by a family limited liability company of which Mr. Thomas is a manager. Mr. Thomas disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
|
|
|
|
|
(14)
|
In his capacity as investment manager for certain managed accounts, Mr. Vassalluzzo may be deemed to have the shared power to vote or to direct the vote of 140,524 shares and to dispose or to direct the disposition of 140,740 shares, which amounts include 138,566 shares held by an employee profit-sharing plan of which Mr. Vassalluzzo is a trustee and in respect of which he disclaims beneficial ownership.
|
|
|
|
|
(15)
|
Mr. Teunissen resigned as Chief Financial Officer in October 2015.
|
|
•
|
Incorporating employees’ annual bonuses into their base salaries.
|
|
•
|
Replacing our current long-term incentive, or LTI, vehicles with a combination of PSUs and cash retention bonuses.
|
|
1.
|
Tightly align compensation incentives to the interests of long-term shareholders.
|
|
2.
|
Establish a pragmatic "proxy" to measure the long-term appreciation (or reduction) of IVPS.
|
|
3.
|
Support a corporate culture of long termism and an "ownership mentality."
|
|
4.
|
Recognize that different employees have different risk appetites.
|
|
5.
|
Reinforce our strong "pay-for-performance" compensation culture.
|
|
1.
|
Tightly align compensation incentives to the interests of our long-term shareholders.
|
|
•
|
PSUs will be settled by issuing Cimpress ordinary shares only upon the achievement of performance targets relative to 6- to 10-year appreciation of a three-year moving average share price.
|
|
•
|
The performance payout targets are defined as annually compounding rates of return in order to take into account the time-value of our shareholders’ invested capital.
|
|
•
|
Payout mechanisms are designed to increase compensation levels based on the degree to which returns exceed our estimated cost of equity, to delay compensation should returns fall below our estimated cost of equity in years 6-9 after the grant of an award, and to decrease or eliminate compensation based on the degree to which ten year compounded returns fall below our estimated cost of equity.
|
|
•
|
The program has a self-regulating aspect: share dilution from PSUs is only triggered upon satisfaction of long-term performance conditions and thus should be reflected in the future share price which is, itself, the basis of the performance metric required for PSU issuance.
|
|
2.
|
Establish a pragmatic “proxy” to measure the long-term appreciation (or reduction) of IVPS.
|
|
3.
|
Support a corporate culture of long termism and “ownership mentality.”
|
|
4.
|
Recognize that different employees have different risk appetites.
|
|
|
Percentage of LTI Grant Value
To Be Granted as PSUs
|
|
|
|
Minimum
|
Maximum
|
|
Robert S. Keane
|
100%
|
100%
|
|
Katryn S. Blake
|
60%
|
100%
|
|
Donald R. Nelson
|
60%
|
100%
|
|
Sean E. Quinn
|
60%
|
100%
|
|
5.
|
Reinforce our strong "pay-for-performance" compensation culture.
|
|
1.
|
Cash Retention Bonuses
|
|
2.
|
Performance Share Units (PSUs)
|
|
3YMA CAGR in year 6, 7, 8, and 9
|
Multiplier to the number of PSUs subject to the award
|
|
11 to 11.99%
|
125.0%
|
|
12 to 12.99%
|
137.5%
|
|
13 to 13.99%
|
150.0%
|
|
14 to 14.99%
|
162.5%
|
|
15 to 15.99%
|
175.0%
|
|
16 to 16.99%
|
187.5%
|
|
17 to 17.99%
|
200.0%
|
|
18 to 18.99%
|
212.5%
|
|
19 to 19.99%
|
225.0%
|
|
20% to 25.8925%
|
250.0%
|
|
Above 25.8925%
|
Variable Cap (defined below)
|
|
3YMA CAGR in year 10
|
Multiplier to the number of PSUs subject to the award
|
|
11% & higher
|
Same as the table above
|
|
10 to 10.99%
|
112.5%
|
|
9 to 9.99%
|
100.0%
|
|
8 to 8.99%
|
87.5%
|
|
7 to 7.99%
|
75.0%
|
|
Less than 7%
|
0%
|
|
•
|
Cimpress will issue no shares under the plan until six years after the initial grant of PSUs, at the earliest.
|
|
•
|
Dilution from the issuance of the maximum number of shares under the plan would not occur until 13 to 17 years after the first grant of PSU awards in fiscal 2017, and it is possible that the maximum number of shares may never be issued.
|
|
Plan Category
|
|
(a) Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights(1) |
|
(b) Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights |
|
(c)
Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column(a) |
|
Equity compensation plans approved by shareholders(1)
|
|
2,913,392
|
|
$45.09
|
|
2,387,435(2)
|
|
Equity compensation plans not approved by shareholders
|
|
—
|
|
—
|
|
—
|
|
Total
|
|
2,913,392
|
|
$45.09
|
|
2,387,435(2)
|
|
(1)
|
|
Consists of our Amended and Restated 2005 Equity Incentive Plan, 2005 Non-Employee Directors’ Share Option Plan, and 2011 Equity Incentive Plan. This column does not include an aggregate of 767,280 shares underlying restricted share units that were unvested as of June 30, 2015.
|
||||
|
|
|
|
||||
|
(2)
|
|
Includes 2,329,411 shares available for future awards under our 2011 Equity Incentive Plan and 58,024 shares available for future awards under our 2005 Non-Employee Directors’ Share Option Plan, as amended. No shares are available for future award under our Amended and Restated 2005 Equity Incentive Plan.
|
||||
|
3YMA
June 2009
|
$32.20
|
|
3YMA
June 2010
|
$38.23
|
|
3YMA
June 2011
|
$41.06
|
|
3YMA
June 2012
|
$43.40
|
|
3YMA
June 2013
|
$38.70
|
|
3YMA
June 2014
|
$40.72
|
|
3YMA
June 2015
|
$52.24
|
|
A
|
B
|
C
|
D
|
E
|
|
Example average
|
Resulting
|
CAGR to August 15th of year specified
|
||
|
price from
|
3YMA
|
11%
|
20%
|
8%
|
|
April 18
|
as of
|
2022
|
2022
|
2025
|
|
to August 15, 2016
|
August 15, 2016
|
(6 years)
|
(6 years)
|
(10 years)
|
|
|
|
Resulting Future 3YMA:
|
||
|
$80.00
|
$67.78
|
$126.78
|
$202.39
|
$146.33
|
|
$90.00
|
$68.89
|
$128.85
|
$205.70
|
$148.73
|
|
$100.00
|
$70.00
|
$130.93
|
$209.02
|
$151.12
|
|
|
|
|
•
|
The options have an exercise price of $50.00 per share, which was at least 33% higher than the closing price of Cimpress' ordinary shares on Nasdaq on the grant dates.
|
|
•
|
Robert Keane, our Chief Executive Officer, has an additional share price hurdle before he can realize any returns from his premium-priced options, which is that, in addition to the vesting schedule described below, he can exercise his options only on dates when the high price per share of Cimpress' ordinary shares on Nasdaq is at least $75.00, which was nearly double the closing price of Cimpress' ordinary shares on the grant dates.
|
|
•
|
To emphasize long-term performance, the options vest over seven years. They have an eight-year term.
|
|
•
|
Our Supervisory Board has passed resolutions that, until fiscal 2016 at the earliest, Cimpress shall not grant any additional long-term incentive award in any form (including equity or long-term cash awards) to Mr. Keane or any additional share options to our other current executive officers.
|
|
•
|
Competitive analysis and recommendations to the Compensation Committee with respect to the compensation of our executive officers;
|
|
•
|
Competitive analysis and recommendations to our Compensation Committee and Chief Executive Officer with respect to the compensation of some of our employees who are not executive officers;
|
|
•
|
Competitive analysis and recommendations to our Compensation Committee with respect to the compensation of members of our Supervisory Board;
|
|
•
|
Detailed equity utilization analysis comparing the number of shares that Cimpress grants per year pursuant to equity compensation awards and the number of shares subject to outstanding equity compensation awards and available for grant under our equity compensation plans with our peer group, to assist the Compensation Committee in setting our practices of granting equity to our employees; and
|
|
•
|
Follow-up assistance for a job leveling solution, including job evaluation technology and supporting tools.
|
|
•
|
Base salary
|
|
•
|
Annual cash incentive awards, which reward executives based on Cimpress' achievement of financial performance goals for the current fiscal year
|
|
•
|
Long-term incentive awards, which may include long-term cash incentives, share options, and restricted share units, which reward executives based on Cimpress' achievement of longer term financial objectives and the creation of value for our shareholders as reflected in our share price
|
|
•
|
Standard health and welfare benefits that are applicable to all of our employees in each executive’s geographic location
|
|
•
|
Base salary of Mr. Keane, our Chief Executive Officer, at the 25th percentile of our peer group
|
|
•
|
Base salaries of our other executive officers at the 35th percentile of our peer group and published compensation surveys
|
|
•
|
Annual cash compensation (base salary and annual cash incentive) of all executive officers including Mr. Keane at the 50th percentile of our peer group and published compensation surveys
|
|
•
|
Total compensation (base salary, annual cash incentive, and long-term incentive awards) of all executive officers including Mr. Keane at the 75th percentile of our peer group and published compensation surveys
|
|
(x)
|
-4.0000 + (2.0000 X Revenue Percentage) + (3.0000 X EPS Percentage); or
|
|
(y)
|
-6.1429 + (2.8571 X Revenue Percentage) + (4.2857 X EPS Percentage)
|
|
•
|
Subtracting from our U.S. GAAP EPS $0.37 for non-operational currency gains including unrealized gains on our hedging programs and the related tax effects and $0.15 for the tax benefit of certain net operating losses that were not assumed when we established our EPS goal; and
|
|
•
|
Adding back to our U.S. GAAP EPS $0.73 relating to the impact of acquisition-related costs and $0.13 relating to incremental interest relative to our EPS goal from our financing that closed during fiscal 2015.
|
|
Name
|
Target Annual
Incentive |
|
Actual Annual
Incentive Paid |
||||
|
Robert S. Keane
|
€
|
756,000
|
|
|
€
|
1,228,500
|
|
|
Katryn S. Blake
|
$
|
335,000
|
|
|
$
|
544,375
|
|
|
Donald R. Nelson
|
$
|
220,000
|
|
|
$
|
357,500
|
|
|
Ernst J. Teunissen
|
€
|
265,000
|
|
|
€
|
430,625
|
|
|
•
|
Our lowest (minimum) EPS goal for fiscal
2015
was $2.67, which would have resulted in a payout of 50% of the named executive officers’ targets for the year;
|
|
•
|
Our medium EPS goal was $3.56, which would have resulted in a payout of 100% of the named executive officers’ targets for the year; and
|
|
•
|
Our highest (stretch) EPS goal was $4.45, which would have resulted in a payout of 250% of the named executive officers’ targets for the year.
|
|
•
|
the payout threshold percentage for the highest EPS target achieved with respect to the fiscal year, plus
|
|
•
|
a number calculated as follows: (A) a percentage equal to a fraction, the numerator of which equals the amount by which adjusted EPS exceeded such applicable EPS goal and the denominator of which equals the difference between the next highest EPS goal that was not achieved and the highest EPS goal achieved, multiplied by (B) the difference between the payout threshold percentage for the next highest EPS goal that was not achieved and the payout threshold percentage for the highest EPS goal achieved.
|
|
Name
|
Target Fiscal 2015 Incentive
($)
|
|
Actual Fiscal 2015 Incentive Paid
($)
|
||||
|
Robert S. Keane
|
$
|
142,500
|
|
|
$
|
103,313
|
|
|
Katryn S. Blake
|
93,750
|
|
|
67,969
|
|
||
|
Donald R. Nelson
|
75,000
|
|
|
54,375
|
|
||
|
Ernst J. Teunissen
|
93,750
|
|
|
67,969
|
|
||
|
•
|
A lump sum severance payment equal to two years’ salary and bonus, in the case of Mr. Keane, or one year’s salary and bonus, in the case of the other executive officers. These severance payments are based on the executive’s then current base salary plus the greater of (1) the target bonus for the then current fiscal year, or (2) the target bonus for the then current fiscal year multiplied by the average actual bonus payout percentage for the previous three fiscal years.
|
|
•
|
With respect to any outstanding annual cash incentive award under our Performance Incentive Plan, a pro rata portion, based on the number of days from the beginning of the then current fiscal year until the date of termination, of his or her target incentive for the fiscal year multiplied by the average actual payout percentage for the previous two fiscal years. If there is no change in control of Cimpress during the fiscal year, this pro rata portion is capped at the actual amount of annual cash incentive that the executive would have received had he or she remained employed by Cimpress through the end of the fiscal year.
|
|
•
|
With respect to any outstanding multi-year cash incentive award under our Performance Incentive Plan, a pro rata portion, based on the number of days from the beginning of the then current performance period until the date of termination, of his or her mid-range target incentive for the then current performance period multiplied by the average actual payout percentage for the previous two fiscal years. If there is no change in control of Cimpress during the applicable performance period, this pro rata portion is capped at the actual amount of cash incentive for the performance period that the executive would have received had he or she remained employed by Cimpress through the end of the performance period.
|
|
•
|
The continuation of all other employment-related benefits for two years after the termination in the case of Mr. Keane, or one year after the termination in the case of our other executive officers.
|
|
Name
|
Cash Payment ($)(1) |
|
Accelerated
Vesting of Share Options ($)(2) |
|
Accelerated
Vesting of Restricted Share Units ($)(3) |
|
Welfare Benefits ($)(4) |
|
Tax Gross-Up Payment ($)(5) |
|
Total ($) |
|||||||
|
Robert S. Keane
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
•
|
Termination Without Cause or With Good Reason
|
2,653,871
|
|
|
—
|
|
|
—
|
|
|
55,824
|
|
|
—
|
|
|
2,709,695
|
|
|
•
|
Change in Control
|
—
|
|
|
26,142,238
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
26,142,238
|
|
|
•
|
Change in Control w/ Termination Without Cause or With Good Reason
|
2,653,871
|
|
|
26,142,238
|
|
|
—
|
|
|
55,824
|
|
|
—
|
|
|
28,851,933
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Katryn S. Blake
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
•
|
Termination Without Cause or With Good Reason
|
700,000
|
|
|
—
|
|
|
—
|
|
|
22,665
|
|
|
—
|
|
|
722,665
|
|
|
•
|
Change in Control
|
—
|
|
|
3,175,924
|
|
|
4,266,155
|
|
|
—
|
|
|
—
|
|
|
7,442,079
|
|
|
•
|
Change in Control w/ Termination Without Cause or With Good Reason
|
700,000
|
|
|
3,175,924
|
|
|
4,266,155
|
|
|
22,665
|
|
|
—
|
|
|
8,164,744
|
|
|
Donald R. Nelson
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
•
|
Termination Without Cause or With Good Reason
|
560,000
|
|
|
—
|
|
|
—
|
|
|
22,381
|
|
|
—
|
|
|
582,381
|
|
|
•
|
Change in Control
|
—
|
|
|
4,124,581
|
|
|
2,922,204
|
|
|
—
|
|
|
—
|
|
|
7,046,785
|
|
|
•
|
Change in Control w/ Termination Without Cause or With Good Reason
|
560,000
|
|
|
4,124,581
|
|
|
2,922,204
|
|
|
22,381
|
|
|
—
|
|
|
7,629,166
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ernst J. Teunissen(6)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
•
|
Termination Without Cause or With Good Reason
|
594,485
|
|
|
—
|
|
|
—
|
|
|
3,941
|
|
|
—
|
|
|
598,426
|
|
|
•
|
Change in Control
|
—
|
|
|
4,811,948
|
|
|
3,083,622
|
|
|
—
|
|
|
—
|
|
|
7,895,570
|
|
|
•
|
Change in Control w/ Termination Without Cause or With Good Reason
|
594,485
|
|
|
4,811,948
|
|
|
3,083,622
|
|
|
3,941
|
|
|
—
|
|
|
8,493,996
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
(1)
|
Amounts in this column represent severance amounts payable under the executive retention agreements. Some of the amounts would be payable to Messrs. Keane and Teunissen in Euros. For purposes of this table, we converted these executive officers’ payments from Euros to U.S. dollars at a currency exchange rate of 1.12167 based on the 30-day average currency exchange rate for June 1-30, 2015, which was the end of our most recent fiscal year.
|
|||||||||||
|
|
|
|||||||||||
|
(2)
|
Amounts in this column represent the value of unvested, in-the-money share options that would vest upon the triggering event described in the first column. The value of share options is based on the difference between the exercise price of the options and $84.16 per share, which was the closing price of our ordinary shares on Nasdaq on June 30, 2015, the last trading day of our fiscal year 2015.
|
|||||||||||
|
|
|
|||||||||||
|
(3)
|
Amounts in this column represent the value of unvested restricted share units that would vest upon the triggering event described in the first column, based on $84.16 per share, which was the closing price of our ordinary shares on Nasdaq on June 30, 2015, the last trading day of our fiscal year 2015.
|
|||||||||||
|
|
|
|||||||||||
|
(4)
|
Amounts reported in this column represent the estimated cost of providing employment related benefits (such as insurance for medical, dental, and vision) during the period the named executive officer is eligible to receive those benefits under the executive retention agreements, which is two years for Mr. Keane and one year for the other named executive officers.
|
|||||||||||
|
|
|
|||||||||||
|
(5)
|
Amounts in this column are estimates based on a number of assumptions and do not necessarily reflect the actual amounts of tax gross-up payments that the named executive officers would receive. Our Compensation Committee decided that we would no longer include such tax gross-up provisions in the executive retention agreements we enter into with new executives after August 1, 2012.
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6)
|
Mr. Teunissen resigned as an executive officer in October 2015.
|
|||||||||||
|
•
|
Chief Executive Officer: 5 times annual base salary
|
|
•
|
Other executive officers: 3 times annual base salary
|
|
•
|
Supervisory Board: 5 times Supervisory Board annual cash retainer
|
|
Name and Principal Position
|
|
Year
|
|
Salary ($) |
|
Share Awards ($)(1) |
|
Option Awards ($)(1) |
|
Non-Equity
Incentive Plan Compensation ($)(2) |
|
All Other Compensation ($) |
|
Total ($) |
|||||
|
Robert S. Keane(3)
|
|
2015
|
|
494,804
|
|
|
—
|
|
|
—
|
|
|
1,481,285
|
|
|
6,200(4)
|
|
1,982,289
|
|
|
President and Chief
|
|
2014
|
|
581,430
|
|
|
—
|
|
|
—
|
|
|
1,161,505
|
|
|
3,109
|
|
1,746,044
|
|
|
Executive Officer
|
|
2013
|
|
559,907
|
|
|
—
|
|
|
3,450,821
|
|
|
1,127,579
|
|
|
3,192
|
|
5,141,499
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Katryn S. Blake
|
|
2015
|
|
365,000
|
|
|
1,205,954
|
|
|
—
|
|
|
612,344
|
|
|
1,104,617(5)
|
|
3,287,915
|
|
|
Executive Vice President and
|
|
2014
|
|
364,231
|
|
|
937,986
|
|
|
—
|
|
|
428,814
|
|
|
546,535
|
|
2,277,566
|
|
|
President, Vistaprint Business Unit
|
|
2013
|
|
344,712
|
|
|
1,004,972
|
|
|
—
|
|
|
425,415
|
|
|
510,294
|
|
2,285,393
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Donald R. Nelson
|
|
2015
|
|
340,000
|
|
|
799,930
|
|
|
—
|
|
|
411,875
|
|
|
7,800(6)
|
|
1,559,605
|
|
|
Executive Vice President and
|
|
2014
|
|
339,808
|
|
|
699,981
|
|
|
—
|
|
|
295,915
|
|
|
7,800
|
|
1,343,504
|
|
|
Chief Operating Officer
|
|
2013
|
|
329,808
|
|
|
649,963
|
|
|
—
|
|
|
309,630
|
|
|
7,650
|
|
1,297,051
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ernst J. Teunissen(3)(8)
|
|
2015
|
|
310,683
|
|
|
799,930
|
|
|
—
|
|
|
550,988
|
|
|
35,067(7)
|
|
1,696,668
|
|
|
Executive Vice President
|
|
2014
|
|
360,706
|
|
|
699,981
|
|
|
—
|
|
|
453,788
|
|
|
40,804
|
|
1,555,279
|
|
|
and Chief Financial Officer
|
|
2013
|
|
320,023
|
|
|
749,996
|
|
|
—
|
|
|
441,530
|
|
|
39,532
|
|
1,551,081
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
The amounts reported in these columns represent a dollar amount equal to the grant date fair value of the share awards as computed in accordance with FASB ASC Topic 718. You can find the assumptions we used in the calculations for these amounts in Note 12 to our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2015. Our Supervisory Board has passed resolutions that, until fiscal 2016 at the earliest, Cimpress will not grant any additional long-term incentive award in any form (including equity or long-term cash awards) to Mr. Keane or any additional share options to Ms. Blake or Messrs. Nelson or Teunissen.
|
|
|
|
|
|
(2)
|
|
The amounts reported in this column represent the aggregate amounts earned for each such fiscal year under each named executive officer’s annual cash incentive award for that fiscal year and the component of each officer’s long-term cash incentive award that is attributable to that fiscal year. You can find more information about the amounts paid for fiscal 2015 to each executive officer under his or her annual and long-term cash incentive awards in the Compensation Discussion and Analysis section of this Supervisory Board Report.
|
|
|
|
|
|
(3)
|
|
We paid the amounts under “Salary,” “Non-Equity Incentive Plan Compensation,” and “All Other Compensation” to Messrs. Keane and Teunissen in whole or in part in Euros. For purposes of this table, we converted these amounts from Euros to U.S. dollars at a currency exchange rate of 1.12167 based on the 30-day average currency exchange rate for June 1-30, 2015, which was the end of our most recent fiscal year.
|
|
(4)
|
|
$4,783 of this amount represents the reimbursement of business travel expenses for Mr. Keane's attendance at meetings of Cimpress' Management Board, tax preparation fees, and associated tax gross-up payments, and $1,417 of this amount represents the payment of wire transfer fees for amounts being deposited in European accounts. Although the reimbursement of business travel expenses would not be taxable to Mr. Keane in the United States and although Mr. Keane is not a resident of the Netherlands, under his ruling with the Dutch tax authorities, this reimbursement is considered taxable income to Mr. Keane. Because Mr. Keane should not be financially penalized as a result of taxation by the country in which Cimpress is incorporated, we gross up the reimbursement payments to offset the increased tax liability to him.
|
||||||||||
|
|
|
|
||||||||||
|
(5)
|
|
$860,604 of this amount represents a lump sum payment of taxes for 2013 and 2014 and associated tax gross-up amounts relating to Ms. Blake's expatriate payments for her assignment in Paris, $236,213 of this amount represents French taxes paid relating to the vesting of restricted share units during Ms. Blake's assignment in Paris, and $7,800 of this amount represents our matching contributions under Cimpress USA’s 401(k) deferred savings plan.
|
||||||||||
|
|
|
|
||||||||||
|
(6)
|
|
This amount represents our matching contributions under Cimpress USA’s 401(k) deferred savings retirement plan.
|
||||||||||
|
|
|
|
||||||||||
|
(7)
|
|
$33,650 of this amount represents payments of school tuition for Mr. Teunissen’s children, and $1,417 of this amount represents the payment of wire transfer fees for amounts being deposited in European accounts.
|
||||||||||
|
|
|
|
||||||||||
|
(8)
|
|
Mr. Teunissen resigned as an executive officer in October 2015.
|
||||||||||
|
|
|
|
|
|
|
All Other
Share Awards: Number of Shares or Share Units |
|
Grant Date Fair Value of Share Awards
|
|||||||||
|
|
|
|
|
Estimated Possible Payouts
|
|
|
|||||||||||
|
|
|
|
|
Under Non-Equity Incentive Plan Awards
|
|
|
|||||||||||
|
|
|
|
|
Threshold
|
|
Target
|
|
Maximum
|
|
|
|||||||
|
Name
|
|
Grant Date
|
|
($)(1)
|
|
($)(2)
|
|
($)(3)
|
|
(#)(4)
|
|
($)(5)
|
|||||
|
Robert S. Keane
|
|
9/28/2014(6)
|
|
—
|
|
|
847,983
|
|
|
1,695,966
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Katryn S. Blake
|
|
9/28/2014
|
|
—
|
|
|
335,000
|
|
|
670,000
|
|
|
—
|
|
|
—
|
|
|
|
|
5/19/2015
|
|
|
|
|
|
|
|
|
|
|
14,331
|
|
|
1,205,954
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Donald R. Nelson
|
|
9/28/2014
|
|
—
|
|
|
220,000
|
|
|
440,000
|
|
|
—
|
|
|
—
|
|
|
|
|
5/19/2015
|
|
|
|
|
|
|
|
|
|
|
9,506
|
|
|
799,930
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ernst J. Teunissen(7)
|
|
9/28/2014(6)
|
|
—
|
|
|
297,243
|
|
|
594,486
|
|
|
—
|
|
|
—
|
|
|
|
|
5/19/2015
|
|
|
|
|
|
|
|
|
|
|
9,506
|
|
|
799,930
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
The amounts reported in this column represent the amounts that would have been payable under our named executive officers’ annual cash incentive awards if we did not achieve our minimum constant currency revenue and adjusted EPS goals.
|
||||||||||||||
|
|
|
|
||||||||||||||
|
(2)
|
|
These amounts represent payments that our named executive officers would have received under their fiscal 2015 annual cash incentive awards for 100% achievement of our adjusted EPS and constant currency revenue goals for fiscal 2015. You can find more information on the amounts actually paid to our executive officers under their fiscal 2015 annual cash incentive awards above in the Compensation Discussion and Analysis section of this Supervisory Board Report.
|
||||||||||||||
|
|
|
|
||||||||||||||
|
(3)
|
|
These amounts represent the maximum amounts that would have been payable under our named executive officers’ annual cash incentive awards for our fiscal year ended June 30, 2015. The payout under each executive officer's annual cash incentive is capped at 200% of the executive officer’s target amount. In fact, based on our achievement of our goals for fiscal 2015, our executive officers received payments that were less than these amounts. You can find more information on the amounts actually paid to our executive officers under their annual cash incentive awards above in the Compensation Discussion and Analysis section of this Supervisory Board Report.
|
||||||||||||||
|
|
|
|
||||||||||||||
|
(4)
|
|
The amounts reported in this column represent restricted share units granted under our 2011 Equity Incentive Plan that vest over a period of four years: 25% one year after they are granted and 6.25% per quarter thereafter. As the restricted share units vest, we automatically issue the vested shares to the employee; the employee does not need to exercise them or pay any amount to us for the purchase of the shares.
|
||||||||||||||
|
|
|
|
||||||||||||||
|
(5)
|
|
The amounts reported in this column represent the grant date fair value for each executive officer’s share-based awards computed in accordance with FASB ASC Topic 718. You can find the assumptions we used in the calculations for these amounts in Note 12 to our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2015.
|
||||||||||||||
|
|
|
|
||||||||||||||
|
(6)
|
|
The estimated amounts in this row would be payable to Messrs. Keane and Teunissen in Euros. For purposes of this table, we converted these estimated incentive payments from Euros to U.S. dollars at a currency exchange rate of 1.12167 based on the 30-day average currency exchange rate for June 1-30, 2015, which was the end of our most recent fiscal year.
|
||||||||||||||
|
|
|
|
||||||||||||||
|
(7)
|
|
Mr. Teunissen resigned as an executive officer in October 2015.
|
||||||||||||||
|
|
|
Option Awards
|
|
Share Awards
|
|||||||||||||
|
|
|
|
|
Number
|
|
Market
|
|||||||||||
|
|
|
|
|
|
|
|
|
of Shares
|
|
Value of
|
|||||||
|
|
|
Number of
|
|
|
|
|
|
or Share
|
|
Shares or
|
|||||||
|
|
|
Securities
|
|
|
|
|
|
Units
|
|
Share
|
|||||||
|
|
|
Underlying
|
|
Option
|
|
|
|
That
|
|
Units That
|
|||||||
|
|
|
Unexercised
|
|
Exercise
|
|
Option
|
|
Have Not
|
|
Have Not
|
|||||||
|
|
|
Options
|
|
Price
|
|
Expiration
|
|
Vested
|
|
Vested
|
|||||||
|
Name
|
|
(#) Exercisable
|
|
(#) Unexercisable
|
|
($)(1)
|
|
Date
|
|
(#)(2)
|
|
($)(3)
|
|||||
|
Robert S. Keane(4)
|
|
130,050
|
|
|
—
|
|
|
23.31
|
|
|
8/4/2016
|
|
|
|
|
|
|
|
|
|
143,618
|
|
|
—
|
|
|
37.51
|
|
|
5/15/2017
|
|
|
|
|
|
|
|
|
|
333,318
|
|
|
—
|
|
|
34.87
|
|
|
5/2/2018
|
|
|
|
|
|
|
|
|
|
146,028
|
|
|
—
|
|
|
34.25
|
|
|
5/7/2019
|
|
|
|
|
|
|
|
|
|
96,800
|
|
|
—
|
|
|
47.91
|
|
|
5/6/2020
|
|
|
|
|
|
|
|
|
|
105,240
|
|
|
—
|
|
|
54.02
|
|
|
5/5/2021
|
|
|
|
|
|
|
|
|
|
459,174
|
|
|
765,288(5)
|
|
|
50.00(6)
|
|
|
5/4/2020(6)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Katryn S. Blake
|
|
1,039
|
|
|
—
|
|
|
54.02
|
|
|
5/5/2021
|
|
|
|
|
|
|
|
|
|
27,892
|
|
|
92,972
|
|
|
50.00(6)
|
|
|
5/4/2020(6)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,691
|
|
|
4,266,155
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Donald R. Nelson
|
|
11,333
|
|
|
—
|
|
|
33.47
|
|
|
8/6/2017
|
|
|
|
|
|
|
|
|
|
6,646
|
|
|
—
|
|
|
54.02
|
|
|
5/5/2021
|
|
|
|
|
|
|
|
|
|
72,446
|
|
|
120,743
|
|
|
50.00(6)
|
|
|
5/4/2020(6)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
34,722
|
|
|
2,922,204
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ernst J. Teunissen(7)
|
|
1,218
|
|
|
—
|
|
|
48.89
|
|
|
3/1/2021
|
|
|
|
|
|
|
|
|
|
1,039
|
|
|
—
|
|
|
54.02
|
|
|
5/5/2021
|
|
|
|
|
|
|
|
|
|
—
|
|
|
140,865
|
|
|
50.00(6)
|
|
|
5/4/2020(6)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
36,640
|
|
|
3,083,622
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
Except as set forth in footnote 6 below, each share option has an exercise price equal to the fair market value of our ordinary shares on the date of grant and becomes exercisable, so long as the named executive officer continues to be employed with us, as to 25% of the shares subject to the option after one year and 6.25% per quarter thereafter. Except as set forth in footnote 6, each share option expires 10 years after the date on which it was granted.
|
|||||||||||
|
|
|
|
|||||||||||
|
(2)
|
|
So long as the named executive officer continues to be employed with us, each restricted share unit vests, and the vested shares are issued to the named executive officer, over a period of four years: 25% of the shares subject to the unit after one year and 6.25% per quarter thereafter.
|
|||||||||||
|
|
|
|
|||||||||||
|
(3)
|
|
The market value of the restricted share units is determined by multiplying the number of restricted share units by $84.16 per share, which was the closing price of our ordinary shares on Nasdaq on June 30, 2015, the last trading day of our fiscal year 2015.
|
|||||||||||
|
|
|
|
|||||||||||
|
(4)
|
|
All of Mr. Keane’s awards are held by his Trusts.
|
|||||||||||
|
|
|
|
|||||||||||
|
(5)
|
|
Mr. Keane may not exercise his premium-priced options unless our share price on Nasdaq is at least $75.00 on the exercise date.
|
|||||||||||
|
|
|
|
|||||||||||
|
(6)
|
|
These awards are premium-priced share options with an exercise price that is significantly higher than the closing price of Cimpress' ordinary shares on Nasdaq on the grant dates. The Compensation Committee chose this exercise price in part because it is higher than the highest of the three-, six-, and twelve-month trailing averages of Cimpress' share price on Nasdaq as of the July 28, 2011 public announcement of our growth strategy. The premium-priced share options vest over seven years and have an eight-year term.
|
|||||||||||
|
|
|
|
|||||||||||
|
(7)
|
|
Mr. Teunissen resigned as an executive officer in October 2015.
|
|||||||||||
|
|
|
Option Awards
|
|
Share Awards
|
||||||||
|
Name
|
|
Number of Shares
Acquired on Exercise (#) |
|
Value Realized on Exercise ($)(1) |
|
Number of Shares
Acquired on Vesting (#) |
|
Value Realized on Vesting ($)(2) |
||||
|
Robert S. Keane
|
|
700,000
|
|
|
48,797,000
|
|
|
10,552
|
|
|
744,839
|
|
|
Katryn S. Blake
|
|
82,152
|
|
|
1,960,283
|
|
|
26,382
|
|
|
1,880,532
|
|
|
Donald R. Nelson
|
|
18,000
|
|
|
603,229
|
|
|
17,579
|
|
|
1,259,980
|
|
|
Ernst J. Teunissen(3)
|
|
110,056
|
|
|
3,582,681
|
|
|
21,350
|
|
|
1,547,915
|
|
|
(1)
|
|
Represents the net amount realized from all option exercises during fiscal 2015. In cases involving an exercise and immediate sale, the value was calculated on the basis of the actual sale price. In cases involving an exercise without immediate sale, the value was calculated on the basis of our closing sale price of our ordinary shares on Nasdaq on the date of exercise.
|
||||||
|
|
|
|
||||||
|
(2)
|
|
The value realized on vesting of restricted share units is determined by multiplying the number of shares that vested by the closing sale price of our ordinary shares on Nasdaq on the vesting date.
|
||||||
|
|
|
|
||||||
|
(3)
|
|
Mr. Teunissen resigned as an executive officer in October 2015.
|
||||||
|
All members of the Supervisory Board
|
●
|
$34,000 retainer per fiscal year
|
|
|
●
|
$10,000 retainer per fiscal year for each committee of the Supervisory Board on which the director serves
|
|
|
●
|
$3,000 for each regularly scheduled Supervisory Board meeting that the director physically attends
|
|
|
|
|
|
Chairman of the Supervisory Board
|
$15,000 retainer per fiscal year
|
|
|
Chairman of our Audit Committee
|
$15,000 retainer per fiscal year
|
|
|
|
|
|
|
Chairmen of our Compensation Committee and Nominating and Corporate Governance Committee
|
$10,000 retainer per fiscal year
|
|
|
Name
|
|
Fees
Earned or Paid in Cash ($) |
|
Share Awards ($)(1) |
|
Option Awards ($)(1) |
|
Total ($) |
||||
|
Paolo De Cesare
|
|
53,000
|
|
|
109,955
|
|
|
49,995
|
|
|
212,950
|
|
|
John J. Gavin, Jr.
|
|
71,000
|
|
|
109,955
|
|
|
49,995
|
|
|
230,950
|
|
|
Peter Gyenes
|
|
66,000
|
|
|
109,955
|
|
|
49,995
|
|
|
225,950
|
|
|
Eric C. Olsen
|
|
61,300
|
|
|
109,955
|
|
|
49,995
|
|
|
221,250
|
|
|
Richard T. Riley
|
|
81,000
|
|
|
109,955
|
|
|
49,995
|
|
|
240,950
|
|
|
Mark T. Thomas
|
|
77,200
|
|
|
109,955
|
|
|
49,995
|
|
|
237,150
|
|
|
Nadia Shouraboura
|
|
18,980
|
|
|
—
|
|
|
149,962
|
|
|
168,942
|
|
|
Scott Vassalluzzo
|
|
27,030
|
|
|
—
|
|
|
149,962
|
|
|
176,992
|
|
|
George M. Overholser(2)
|
|
48,680
|
|
|
109,955
|
|
|
49,995
|
|
|
208,630
|
|
|
(1)
|
|
The value of the share awards equals their grant date fair value as computed in accordance with FASB ASC Topic 718. You can find the assumptions we used in the calculations for these amounts in Note 12 to our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2015. All share options referenced in this table were granted with an exercise price equal to the closing price of our ordinary shares on Nasdaq on the date of grant.
|
||||||||
|
|
|
|
||||||||
|
(2)
|
|
Mr. Overholser resigned as a director effective February 2015.
|
||||||||
|
|
|
Option Awards
|
|
Share Awards
|
|||||||||||||
|
|
|
|
|
Number
|
|
Market
|
|||||||||||
|
|
|
|
|
|
|
|
|
of Shares
|
|
Value of
|
|||||||
|
|
|
Number of
|
|
|
|
|
|
or Share
|
|
Shares or
|
|||||||
|
|
|
Securities
|
|
|
|
|
|
Units
|
|
Share
|
|||||||
|
|
|
Underlying
|
|
Option
|
|
|
|
That
|
|
Units That
|
|||||||
|
|
|
Unexercised
|
|
Exercise
|
|
Option
|
|
Have Not
|
|
Have Not
|
|||||||
|
|
|
Options
|
|
Price
|
|
Expiration
|
|
Vested
|
|
Vested
|
|||||||
|
Name
|
|
(#) Exercisable
|
|
(#) Unexercisable
|
|
($)(1)
|
|
Date
|
|
(2)(#)
|
|
(3)($)
|
|||||
|
Paolo De Cesare
|
|
4,669
|
|
|
2,335
|
|
|
40.80
|
|
|
4/30/2023
|
|
|
|
|
|
|
|
|
|
888
|
|
|
888
|
|
|
54.08
|
|
|
11/7/2023
|
|
|
|
|
|
|
|
|
|
241
|
|
|
1210
|
|
|
68.38
|
|
|
11/12/2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,735
|
|
|
230,178
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
John J. Gavin, Jr.
|
|
12,018
|
|
|
—
|
|
|
24.32
|
|
|
8/21/2016
|
|
|
|
|
|
|
|
|
|
2,925
|
|
|
—
|
|
|
33.24
|
|
|
11/14/2016
|
|
|
|
|
|
|
|
|
|
2,269
|
|
|
—
|
|
|
46.18
|
|
|
11/2/2017
|
|
|
|
|
|
|
|
|
|
9,548
|
|
|
—
|
|
|
15.94
|
|
|
11/7/2018
|
|
|
|
|
|
|
|
|
|
1,919
|
|
|
—
|
|
|
54.46
|
|
|
11/17/2019
|
|
|
|
|
|
|
|
|
|
2,443
|
|
|
—
|
|
|
40.99
|
|
|
11/12/2020
|
|
|
|
|
|
|
|
|
|
2,690
|
|
|
—
|
|
|
35.77
|
|
|
11/3/2021
|
|
|
|
|
|
|
|
|
|
2,645
|
|
|
530
|
|
|
30.30
|
|
|
11/8/2022
|
|
|
|
|
|
|
|
|
|
888
|
|
|
888
|
|
|
54.08
|
|
|
11/7/2023
|
|
|
|
|
|
|
|
|
|
241
|
|
|
1,210
|
|
|
68.38
|
|
|
11/12/2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,319
|
|
|
195,167
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Peter Gyenes
|
|
7,389
|
|
|
—
|
|
|
24.33
|
|
|
2/5/2019
|
|
|
|
|
|
|
|
|
|
1,919
|
|
|
—
|
|
|
54.46
|
|
|
11/17/2019
|
|
|
|
|
|
|
|
|
|
2,443
|
|
|
—
|
|
|
40.99
|
|
|
11/12/2020
|
|
|
|
|
|
|
|
|
|
2,690
|
|
|
—
|
|
|
35.77
|
|
|
11/3/2021
|
|
|
|
|
|
|
|
|
|
2,645
|
|
|
530
|
|
|
30.30
|
|
|
11/8/2022
|
|
|
|
|
|
|
|
|
|
888
|
|
|
888
|
|
|
54.08
|
|
|
11/7/2023
|
|
|
|
|
|
|
|
|
|
241
|
|
|
1210
|
|
|
68.38
|
|
|
11/12/2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,319
|
|
|
195,167
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Eric C. Olsen
|
|
4,669
|
|
|
2,335
|
|
|
40.80
|
|
|
4/30/2023
|
|
|
|
|
|
|
|
|
|
888
|
|
|
888
|
|
|
54.08
|
|
|
11/7/2023
|
|
|
|
|
|
|
|
|
|
241
|
|
|
1210
|
|
|
68.38
|
|
|
11/12/2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,735
|
|
|
230,178
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Richard T. Riley
|
|
2,925
|
|
|
—
|
|
|
33.24
|
|
|
11/14/2016
|
|
|
|
|
|
|
|
|
|
2,269
|
|
|
—
|
|
|
46.18
|
|
|
11/2/2017
|
|
|
|
|
|
|
|
|
|
9,548
|
|
|
—
|
|
|
15.94
|
|
|
11/7/2018
|
|
|
|
|
|
|
|
|
|
1,919
|
|
|
—
|
|
|
54.46
|
|
|
11/17/2019
|
|
|
|
|
|
|
|
|
|
2,443
|
|
|
—
|
|
|
40.99
|
|
|
11/12/2020
|
|
|
|
|
|
|
|
|
|
2,690
|
|
|
—
|
|
|
35.77
|
|
|
11/3/2021
|
|
|
|
|
|
|
|
|
|
2,645
|
|
|
530
|
|
|
30.30
|
|
|
11/8/2022
|
|
|
|
|
|
|
|
|
|
888
|
|
|
888
|
|
|
54.08
|
|
|
11/7/2023
|
|
|
|
|
|
|
|
|
|
241
|
|
|
1,210
|
|
|
68.38
|
|
|
11/12/2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,319
|
|
|
195,167
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nadia Shouraboura
|
|
332
|
|
|
3,657
|
|
|
79.52
|
|
|
2/3/2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mark T. Thomas
|
|
5,758
|
|
|
—
|
|
|
54.46
|
|
|
11/17/2019
|
|
|
|
|
|
|
|
|
|
2,443
|
|
|
—
|
|
|
40.99
|
|
|
11/12/2020
|
|
|
|
|
|
|
|
|
|
2,690
|
|
|
—
|
|
|
35.77
|
|
|
11/3/2021
|
|
|
|
|
|
|
|
|
|
2,645
|
|
|
530
|
|
|
30.30
|
|
|
11/8/2022
|
|
|
|
|
|
|
|
|
|
888
|
|
|
888
|
|
|
54.08
|
|
|
11/7/2023
|
|
|
|
|
|
|
|
|
|
241
|
|
|
1210
|
|
|
68.38
|
|
|
11/12/2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,319
|
|
|
195,167
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Scott Vassalluzzo
|
|
332
|
|
|
3,657
|
|
|
79.52
|
|
|
2/3/2025
|
|
|
|
|
|
|
|
(1)
|
|
Each share option has an exercise price equal to the fair market value of our ordinary shares on the date of grant and becomes exercisable at a rate of 8.33% per quarter over a period of three years from the date of grant, so long as the Supervisory Board member continues to serve as a director on each such vesting date. Each share option expires 10 years after the date on which it was granted.
|
|||||||||||
|
|
|
|
|||||||||||
|
(2)
|
|
Upon the vesting of each restricted share unit, shares are issued to the director on a one-to-one basis. Restricted share units issued to Supervisory Board members before July 1, 2013 vest as to 8.33% of the shares subject to the unit per quarter over a period of three years, so long as the director continues to serve as a director on each such vesting date. Restricted share units issued to Supervisory Board members after July 1, 2013 vest as to 12.5% of the shares subject to the unit per quarter over a period of two years, so long as the director continues to serve as a director on each such vesting date.
|
|||||||||||
|
|
|
|
|||||||||||
|
(3)
|
|
The market value of the restricted share units is determined by multiplying the number of restricted share units by $84.16 per share, which was the closing price of our ordinary shares on Nasdaq on June 30, 2015, the last trading day of our fiscal year 2015.
|
|||||||||||
|
•
|
Free cash flow is defined as net cash provided by operating activities less purchases of property, plant and equipment, purchases of intangible assets not related to acquisitions, and capitalization of software and website development costs, plus payment of contingent consideration in excess of acquisition-date fair value.
|
|
•
|
Adjusted NOPAT is defined as GAAP Operating Income minus cash taxes attributable to the current period (see definition below), with the following adjustments: exclude the impact of M&A related items including amortization of acquisition-related intangibles, the change in fair value of contingent consideration, and expense for deferred payments or equity awards that are treated as compensation expense; exclude the impact of unusual items such as discontinued operations, restructuring charges, and impairments; and include realized gains or losses from currency forward contracts that are not included in operating income as we do not apply hedge accounting.
|
|
•
|
As part of our calculation of Adjusted NOPAT, we subtract the cash taxes attributable to the current period operations, which we define as the actual cash taxes paid or to be paid adjusted for any non-operational items and excluding the excess tax benefit from equity awards.
|
|
|
2013
|
2014
|
2015
|
|
Net cash provided by operating activities
|
$140,012
|
$148,580
|
$228,876
|
|
Purchase of property, plant, and equipment
|
(78,999)
|
(72,122)
|
(75,813)
|
|
Purchases of intangible assets not related to acquisitions
|
(750)
|
(253)
|
(250)
|
|
Capitalization of software and website development costs
|
(7,667)
|
(9,749)
|
(17,323)
|
|
Payment of contingent consideration in excess of acquisition-date fair value
|
0
|
0
|
8,055
|
|
Free Cash Flow
|
$52,596
|
$66,456
|
$143,545
|
|
|
2013
|
2014
|
2015
|
|||
|
GAAP operating income
|
$46.1
|
|
$85.9
|
|
$96.3
|
|
|
Less
: Cash taxes attributable to current period (see separate reconciliation below)
|
$(14.0)
|
|
$(20.1)
|
|
$(25.0)
|
|
|
Exclude expense (benefit) impact of
:
|
|
|
|
|||
|
Amortization of acquisition-related intangible assets
|
10.9
|
|
12.6
|
|
24.3
|
|
|
Earn-out related charges
Includes expense recognized for the change in fair value of contingent consideration and compensation expense related to cash-based earn-out mechanisms dependent upon continued employment.
|
(0.6
|
)
|
2.2
|
|
15.3
|
|
|
Share-based compensation related to investment consideration
|
7.9
|
|
4.4
|
|
3.6
|
|
|
Restructuring charges
|
-
|
|
6.0
|
|
3.2
|
|
|
Include
: Realized gain (loss) on currency forward contracts not included in operating income
|
-
|
|
(7
|
)
|
7.4
|
|
|
Adjusted NOPAT
|
$50.3
|
|
$84.0
|
|
$125.1
|
|
|
|
2013
|
2014
|
2015
|
|||
|
Cash taxes paid in the current period
|
$13.7
|
|
$18.5
|
|
$14.3
|
|
|
Less
: cash taxes related to prior periods
|
(0.5
|
)
|
(6.5
|
)
|
(5.5
|
)
|
|
Plus
: cash taxes attributable to the current period but not yet paid
|
2.9
|
6.0
|
6.7
|
|
||
|
Plus
: cash impact of excess tax benefit on equity awards attributable to current period
|
$1.4
|
|
$5.6
|
|
12.9
|
|
|
Less
: installment payment related to the transfer of IP in a prior year
|
$(3.4)
|
|
$(3.4)
|
|
(3.4
|
)
|
|
Cash taxes attributable to current period
|
$14.0
|
|
$20.1
|
|
$25.0
|
|
|
1.
|
Purpose
|
|
2.
|
Eligibility
|
|
3.
|
Administration and Delegation
|
|
4.
|
Shares Available for Awards
|
|
5.
|
Performance Share Units
|
|
6.
|
Section 162(m) Provisions
|
|
7.
|
Adjustments for Changes in Shares and Certain Other Events
|
|
8.
|
General Provisions Applicable to Awards
|
|
9.
|
Miscellaneous
|
|
CAGR
as of the
Measurement Date
|
Multiplier to the number of PSUs subject to the Award
|
|
11 to 11.99%
|
125.0%
|
|
12 to 12.99%
|
137.5%
|
|
13 to 13.99%
|
150.0%
|
|
14 to 14.99%
|
162.5%
|
|
15 to 15.99%
|
175.0%
|
|
16 to 16.99%
|
187.5%
|
|
17 to 17.99%
|
200.0%
|
|
18 to 18.99%
|
212.5%
|
|
19 to 19.99%
|
225.0%
|
|
20% to 25.8925%
|
250.0%
|
|
25.8925% or above
|
Variable Cap (as defined below)
|
|
CAGR
as of the Measurement Date
|
Multiplier to the number of PSUs subject to the Award
|
|
11% & higher
|
Same as the table above
|
|
10 to 10.99%
|
112.5%
|
|
9 to 9.99%
|
100.0%
|
|
8 to 8.99%
|
87.5%
|
|
7 to 7.99%
|
75.0%
|
|
Less than 7%
|
0%
|
|
•
|
Enable us to attract and retain superior talent
|
|
•
|
Provide competitive incentives to motivate people toward their highest performance
|
|
•
|
Provide mechanisms that result in remuneration above peer averages as a means to reward extraordinary performance and below peer averages in the absence of extraordinary performance
|
|
•
|
Promote fair and equitable treatment relative to rewards, considering both internal and external comparisons
|
|
•
|
Align executive and shareholder interests by utilizing compensation vehicles and program structure that reward long-term shareholder value creation
|
|
•
|
Evaluate and refine all compensation programs in light of the Company’s strategic direction and life cycle stage, external market data, the practices of companies of a similar size and profile (“peers”), the Company’s overall remuneration policies and the overall affordability of compensation packages.
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|